November 5, 2025 7:17am

As earnings come with sentiment and expectation restraints, revenue declines, consensus and EPS misses following some with drug failures and regulatory concerns

Traders are looking to the ADP private payrolls report for clues about the labor market, alongside updates on mortgage applications and ISM services activity

News: Mesoblast (MESO) the FDA has scheduled a meeting in early December to discuss its data on opioid reduction and cessation from its 1st P3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain (CLBP). The “FDA has emphasized the importance of developing non opioid treatments for chronic pain, and we look forward to discussing plans for rexlemestrocel-L as an agent that may result in both amelioration of CLBP as well as opioid reduction or cessation.”

Pre-open Signals: 3 Negative and 5 Positive Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

 

Also, President Trump's tariffs face a key test when the Supreme Court hears arguments in a case questioning his legal authority to impose sweeping duties. The high court's ultimate decision could have significant reverberations for the global economy.

Tuesday night’s … RMi Closing Bell: Fear … https://www.regmedinvestors.com/articles/14181

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Wednesday: The pre-open Dow futures are DOWN -0.07% or (-34 points), the S&P futures are DOWN -0.25% or (-17 points) and the Nasdaq futures are DOWN -0.39% or (-101 points)

  • Stock futures were lower, Wednesday, 11/5
  • European markets opened lower,
  • Asia Pacific markets fell

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed DOWN -251.07 points or -0.53%, the S&P closed DOWN -80.30 points or -1.17% while the Nasdaq closed DOWN -486.087 points or -2.04%
  • Monday: The Dow closed DOWN -226.19 points or -0.48%, the S&P closed UP +11.77 points or +0.17% while the Nasdaq closed UP +109,766 points or +0.46%
  • Last week: The S&P 500 was up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%
  • The previous week: the S&P 500 was up +2%, the Dow +2% and the Nasdaq added +2%.
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.
  • 2025 to date: the S&P is up +16%, the Nasdaq +22% and thew Dow +12%

 

Q4 – November, 2 negative sessions

  • October, 1 neutral, 10 positive and 12 negative closes
  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Info:

Supernus Therapeutics (SUPN) closed up +$1.30 after Monday’s +$0.57 with a negative -$2.75 or -4.82% pre-open

BioNTech (BNTX) closed up +$0.88 after Monday’s +$0.04 with a negative -$1.48 or -1.41% pre-open

AxoGen (AXGN) closed up +$0.52 after Monday’s +$1.03 with a positive +$0.13 or +0.55% pre-open

Sarepta Therapeutics (SRPT) closed down -$8.25 after Monday’s +$0.44 with a positive +$0.50 or +3.09% pre-open

CRISPR Therapeutics (CRSP) closed down -$5.56 after Monday’s -$2.02 with a positive +$0.49 or +0.87% pre-open

uniQure NV (QURE) closed down -$3.85 after Monday’s -$33.40 with a negative -$2.44 or -9.02% pre-open

Arrowhead Pharma (ARWR) closed down -$1.76 after Monday’s -$2.78 with a positive +$0.05 or +0.13% pre-open

Moderna (MRNA) closed down -$1.16 after Monday’s -$2.25 with a positive +$0.22 or +0.93% pre-open

 

The BOTTOM LINE: Feeling the drag…

The 2nd trading day of November began on a downcast note while earnings reports keep getting released.

  • As the government shutdown continues becoming the longest in American history.
  • A rough trading session that saw all 3 indexes closing deeply in the red

I got on my computer/laptop/ my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Q3 Earnings this week: Regenxbio (RGNX), Moderna (MRNA) and Vericel (VCEL) on 11/6, followed by Cellectis SA CLLS) on 11/7 with Capricor Therapeutics (CAPR) on 11/10

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

  • As sector earnings meet, beat or miss expectations; whipsaw actions could ensue depreciations or the stock market heads south, back pedal -- fast.

The shutdown enters its 34th day and 6th today, with lawmakers still unable to agree on a funding bill … as Democrats block the 13th voting negotiation

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow review some of October:

This week;

  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

Last week:

  • 10/31 – Friday closed positive with 28 positive, 11 negative and 1 flat
  • 10/30 – Thursday closed negative with 13 positive, 25 negative and 2 flats
  • 10/29 - Wednesday closed negative with 9 positive, 30 negative and 1 flat
  • 10/28 -Tuesday closed negative with 16 positive, 21 negative and 3 flats
  • 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.